A prognostic model for survival after palliative urinary diversion for malignant ureteric obstruction: a prospective study of 208 patients
Carregando...
Citações na Scopus
42
Tipo de produção
article
Data de publicação
2016
Título da Revista
ISSN da Revista
Título do Volume
Editora
WILEY-BLACKWELL
Citação
BJU INTERNATIONAL, v.117, n.2, p.266-271, 2016
Resumo
Objective To identify factors associated with survival after palliative urinary diversion (UD) for patients with malignant ureteric obstruction (MUO) and create a risk-stratification model for treatment decisions. Patients and Methods We prospectively collected clinical and laboratory data for patients who underwent palliative UD by ureteric stenting or percutaneous nephrostomy (PCN) between 1 January 2009 and 1 November 2011 in two tertiary care university hospitals, with a minimum 6-month follow-up. Inclusion criteria were age >18 years and MUO confirmed by computed tomography, ultrasonography or magnetic resonance imaging. Factors related to poor prognosis were identified by Cox univariable and multivariable regression analyses, and a risk stratification model was created by Kaplan-Meier survival estimates at 1, 6 and 12 months, and log-rank tests. Results The median (range) survival was 144 (0-1084) days for the 208 patients included after UD (58 ureteric stenting, 150 PCN); 164 patients died, 44 (21.2%) during hospitalisation. Overall survival did not differ by UD type (P = 0.216). The number of events related to malignancy (>= 4) and Eastern Cooperative Oncology Group (ECOG) index (> 2) were associated with short survival on multivariable analysis. These two risk factors were used to divide patients into three groups by survival type: favourable (no factors), intermediate (one factor) and unfavourable (two factors). The median survival at 1, 6, and 12 months was 94.4%, 57.3% and 44.9% in the favourable group; 78.0%, 36.3%, and 15.5% in the intermediate group; and 46.4%, 14.3%, and 7.1% in the unfavourable group (P < 0.001). Conclusions Our stratification model may be useful to determine whether UD is indicated for patients with MUO.
Palavras-chave
hydronephrosis, palliative surgery, percutaneous nephrostomy, stent, survival, ureteric obstruction
Referências
- Ishioka J, 2008, J UROLOGY, V180, P618, DOI 10.1016/j.juro.2008.04.011
- Rosenberg BH, 2005, J ENDOUROL, V19, P63, DOI 10.1089/end.2005.19.63
- Donat SM, 1996, ANN SURG ONCOL, V3, P393, DOI 10.1007/BF02305670
- Lienert A, 2009, BJU INT, V104, P938, DOI 10.1111/j.1464-410X.2009.08492.x
- Izumi K, 2011, J UROLOGY, V185, P556, DOI 10.1016/j.juro.2010.09.102
- ZIMSKIND PD, 1967, J UROLOGY, V97, P840
- Shekarriz B, 1999, CANCER, V85, P998, DOI 10.1002/(SICI)1097-0142(19990215)85:4<998::AID-CNCR30>3.0.CO;2-F
- HOLDEN S, 1979, J UROLOGY, V121, P19
- Ganatra AM, 2005, J UROLOGY, V174, P2125, DOI 10.1097/01.ju.0000181807.56114.b7
- Monsky WL, 2013, CARDIOVASC INTER RAD, V36, P1355, DOI 10.1007/s00270-013-0571-9
- ZADRA JA, 1987, CANCER, V60, P1353, DOI 10.1002/1097-0142(19870915)60:6<1353::AID-CNCR2820600632>3.0.CO;2-5
- Wong LM, 2007, J UROLOGY, V178, P178, DOI 10.1016/j.juro.2007.03.026
- FERNBACH SK, 1993, PEDIATR RADIOL, V23, P478, DOI 10.1007/BF02012459
- Emmert C, 1997, ARCH GYNECOL OBSTET, V259, P147, DOI 10.1007/BF02505324
- PUPPO P, 1995, EUR UROL, V28, P328
- Dienstmann R, 2008, J PAIN SYMPTOM MANAG, V36, P185, DOI 10.1016/j.jpainsymman.2007.09.010
- Russo P, 2005, J UROLOGY, V174, P2088, DOI 10.1097/01.ju.0000187105.30751.77
- CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8
- GOODWIN WE, 1955, JAMA-J AM MED ASSOC, V157, P891
- Colombel M, 1997, EUR UROL, V31, P21
- FALLON B, 1980, BRIT J UROL, V52, P237, DOI 10.1111/j.1464-410X.1980.tb08909.x
- VILLAVICENCIO H, 1993, EUR UROL, V24, P118
- de Borja Maria-Theresa, 2004, Support Cancer Ther, V2, P59, DOI 10.3816/SCT.2004.n.024
- Grasa V, 2004, An Sist Sanit Navar, V27 Suppl 3, P125, DOI 10.4321/s1137-66272004000600013